Study of sotatercept for Eisenmenger syndrome patients
Treatments studied
Part of Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a heart defect (hole) that hasn't been repaired, such as a hole between the upper or lower chambers of the heart or a duct that didn't close after birth
- You have been taking medication for high blood pressure in your lungs (pulmonary hypertension) for at least 3 months
- You have moderate or severe pulmonary hypertension based on recent tests
- You can walk at least 100 meters in 6 minutes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sotatercept, for people with a heart defect present at birth that has led to Eisenmenger syndrome. The drug may help improve exercise ability and overall well-being.
This study tests an investigational drug called sotatercept for people who have a specific type of high blood pressure in the lungs that happens along with heart failure with preserved ejection fraction (a stiff heart muscle). The treatment aims to improve your ability to be active and reduce symptoms, and the study will compare it to a placebo to see if it helps.
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
Hear when a new Eisenmenger Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.